Skip to main content
Medical information Clinical review pending

Genetic Testing

TGFBR2 Gene Aortic Aneurysm Familial Thoracic Type 3 Genetic Test

This genetic test identifies mutations in the TGFBR2 gene associated with Familial Thoracic Aortic Aneurysm Type 3. It helps assess risk for individuals with a family history of this condition, enabling proactive health management.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
Results
Approximately 3 to 4 weeks. Confirm with the laboratory before booking.
Preparation
A clinical history of the patient is required. A genetic counseling session to draw a pedigree chart of affected family members is recommended before testing.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the TGFBR2 Gene Aortic Aneurysm Familial Thoracic Type 3 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Family history of thoracic aortic aneurysms
  • ✓Individuals with symptoms suggestive of aortic aneurysm (e.g., chest or back pain)
  • ✓Patients with known vascular diseases
  • ✓Genetic counseling for families with affected members
  • ✓Risk assessment for individuals with suspected genetic predisposition
02

In plain language

What this test helps you understand

Identifies genetic mutations in the TGFBR2 gene associated with Familial Thoracic Aortic Aneurysm Type 3. Helps assess individual risk and informs management strategies for vascular diseases.
The TGFBR2 Gene Aortic Aneurysm Familial Thoracic Type 3 NGS Genetic DNA Test is an advanced diagnostic tool used to identify specific genetic mutations linked to thoracic aortic aneurysms. Understanding your genetic predisposition is important for the early detection and management of vascular diseases, especially if you have a family history of such conditions.

This test focuses on detecting mutations within the TGFBR2 gene. This gene provides instructions for making a protein involved in cell growth, differentiation, and apoptosis (programmed cell death). Mutations in this gene can disrupt normal vascular function and increase the risk of developing aortic aneurysms.

This test is recommended for individuals with a family history of thoracic aortic aneurysms, those experiencing related symptoms, or patients with known vascular diseases. Early detection allows for proactive health management, informed decisions about lifestyle and medical interventions, and a better understanding of familial health risks.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA clinical history of the patient is required. A genetic counseling session to draw a pedigree chart of affected family members is recommended before testing.
SampleBlood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
MethodologyNext-Generation Sequencing (NGS) of the TGFBR2 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test only detects mutations within the TGFBR2 gene. It does not rule out other genetic or non-genetic causes of aortic aneurysms. A negative result does not completely eliminate the risk. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This is a genetic condition characterized by the enlargement (aneurysm) of the aorta, the main artery carrying blood from the heart. Type 3 specifically refers to a particular genetic pattern associated with the TGFBR2 gene.
Individuals with a family history of thoracic aortic aneurysms, those experiencing symptoms like chest or back pain, or those advised by their doctor due to other risk factors should consider this test.
A positive result indicates the presence of a mutation in the TGFBR2 gene associated with Familial Thoracic Aortic Aneurysm Type 3. It suggests an increased risk and warrants discussion with a healthcare provider regarding management.
A negative result means no mutations associated with this condition were detected in the tested gene. However, it does not completely rule out the possibility of other genetic causes or the condition itself. Discuss the result with your doctor.
Yes, genetic counseling is recommended before testing to understand the implications, benefits, and limitations of the test, and to help interpret the results in the context of your family history.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp